If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
Some delayed 1million + whackers landing - printed on the median - grey trades
Wouldn’t surprise me if shorts closing ,Shall check totals tomorrow
28-Mar-24 13:54:07 1.74545 1,070,000 Unknown* 1.73 1.76 18.68k O
28-Mar-24 13:28:52 1.73 1,500,000 Unknown* 1.72 1.76 25.95k O
28-Mar-24 12:49:05 1.742 1,250,000 Unknown* 1.72 1.755 21.78k O
Morning all invested
Last days trading before Easter break .
The Hemo science cogs & clinical preparation underpinned by Prevail will be ticking on & news will follow .
Despite the recent placement & imo temporary stock level , Hemo are in a good position & the stock will gain traction once news begins to flow , today ? , next week ….
Many bogged down with the placement & current stock price & certainly highlights the hidden toxicity with shorts taking advantage of the placement drop & still desperate for a nibble .
Currently 4 .2 million
however look beyond at what Hemo has achieved & what’s now coming ,invest with patience based on the RNS , current stock a dry powder given imo .
Some large delayed buys in recent sessions 3.5 mill etc
CAR T - Clinical & underpinned by Prevail .
CDX - cooking
CBR - - virus eradication & Brain delivery
& now plenty of cash in the Bank to get to clinical & Vlads recent proactive investor interview very positive . ‘ substantial rewards for patients & shareholders ‘
Trading indicators moved to buy Friday - investing.com
Recent noted interviews on stock picks - highlighting Hemo as a bullish now placement done with good potential upside with Hemo science & stock potential.
Let’s see where the stock is in months to come imo , not at the current levels .
Closing price 1.745 - a gnats eyelash off flat - 0.03%
No blue - all trades within the huge spread
Volume 8 million - thin
Vwap 1.75
Delayed trade after the bell printed as a sell
Date Time Trade Prc Volume Buy/Sell Bid Ask Value
27-Mar-24 16:31:11 1.75 1,000,000 Sell* 1.74 1.785 17.50k
Will check stock on loan / shorts later & see if any other delayed trades land
All invested await next RNS with clinical update
The placement churn finished other week , imo
Majority if not all forward sold .
AI bots in control in recent week & a large spread allows lots of movement to bag pennys within the spread & for the record as noted by myself
Stock on loan / shorts
5 million were opened @ 1.6 ish other week
800 k closed Monday
& I suspect more to close today / tomorrow & likely associated to some of the negativity on here in recent weeks .
They tried to push the stock lower , got greedy & now the stock cautiously sits higher .
Let’s see what today , tomorrow & next week brings .
Evening all
Increase in vol - 15 million today
4 million in delayed trades as noted earlier
Shorts reducing 800k yesterday- as noted via Ortex
RSI - jumped to 65 this week
Trading indicators have swung to strong buy
Looks to me like potential whiff of RNS in the pipeline , let’s see what volume is like tomorrow & I will confirm if shorts reduced
Cash in the Bank & clinical
We all know Vlad & underpinned by Prevail are grafting into clinical
Not forgetting CDX & CBR cooking
Imo - a gift to purchase at current levels with potential in the pipeline .
Recent Share Trades for Hemogenyx (HEMO)
JFTH , Chris , & All
Some decent kippers after the bell
Last eves delayed 800k was a short closing
I will check tonight on Ortex & see if any of those are further reducing recent shorts opened
Date Time Trade Prc Volume Buy/Sell Bid Ask Value
26-Mar-24 17:07:48 1.775 500,000 Unknown* 1.755 1.795 8,875 O
26-Mar-24 16:37:53 1.755 3,750,000 Buy* 1.755 1.795 65.81k O
26-Mar-24 16:37:37 1.755 250,000 Buy* 1.755 1.795 4,388 O
Looks like the shorting crew have gone it wrong as reversal continues
Afternoon all
To note the cautious reversal continues …
Yes 2% but in the right direction slowly we need vol & an RNS to surge north .
1.76 paid
Vwap 1.73
Volume 6 million
Buyers outstripping sellers
Looks like some of shorts closed yesterday, who opened at 1.6
The delayed 800 k trade after the bell was a short closing
25-Mar-24 16:37:00 1.704 800,000 Unknown* 1.695 1.75 13.63k O
Ortex - showing 4.2 million stock on loan
& looks like they are getting their backsides kicked as opened last week .
Likely associated to some of the negativity on these forums .
Clinical with cash in the bank & other science cooking is good enough for myself .
Nice delayed kipper just landed - printed in the median - grey trade
25-Mar-24 16:37:00 1.704 800,000 Unknown* 1.695 1.75 13.63k O
Low volume 3.5 million -
Yet showing blue +1% - all manoeuvres within the spread
Vwap 1.705
This moot character who has sprung up coincidentally the same time as a short was opened at 1.6 , unfortunately the stock has gone north since .
Perhaps be a sleeper account as not posted for a yr & straight on here , after bombarding ciz .
Some crazy cooters with crazy agenda on these forums & stand out like a Mandrills backside in heat .
Orph & all - Morning
Unfortunately these forums are awash with toxic traders reeking of agenda ,
desperate to be ‘ Wolf of Wall St ‘ however only managed ‘ Mudskipper of Bog St ‘
The figures don’t lie & neither does company news ,
huge risk to open a short at sub current price , imo & hope they get their backsides napalmed
Fetch the Sunday bacon banjos
Morning all invested
Shorters can kiss my leathery ass 👍
Stock on loan / shorts
Currently 5.07 million - value 87k
( a 3.25 million short was opened on Friday 15th /mon 18th at that stage price was 1.6 &- obviously wanting the price lower ,)
- the week previous a 1.75 million short was opened & still open .hence 5 million total
( ties in with recent negativity on this & other forums , connected ? i think so as been on these boards for yrs & seen all the toxic trading patterns
, unfortunately the stock is going the wrong direction for the bozos this week closing at 1.72
To much buying demand , let’s hope a positive RNS drops Monday & napalms their backsides .
Cost to borrow 14
No flagged shorts
Volume Friday - 6.2 million
Average 3 month vol - 15 million
Trading - investing .com
RSI - has jumped to 54
indicators have moved positive to strong buy with Fridays close above 1.71
All above for info purposes & none will matter with a positive CAR T update with potential pharma deal , current price will be Broadsided .imo
Especially re reading recent RNS & watch latest interview .
Fetch the Full English with all the trimmings including black pudding
6. Cartherics to Try CAR-NK Cell Therapy Targeted at Tissue Factor Via Agreement With Ohio State University
Cartherics has executed an option agreement for research using intellectual property from The Ohio State University that covers the use of CAR natural killer (NK) cell therapy to target tissue factor (TF), a coagulation factor expressed in some tumor tissues and tumor blood vessels.
7. Hemogenyx Garners $4.2 Million Via Placing Shares
The company will put the net proceeds from this move towards HEMO-CAR-T, its CAR-T therapy that has been cleared by the FDA for a phase 1 clinical trial in patients with acute myeloid leukemia. "This is a key development that represents the progression of Hemogenyx Pharmaceuticals to become a clinical stage company and the fundraise was crucial to enable us to progress toward clinical trials, the essential next step for the development of HEMO-CAR-T," Vladislav Sandler, PhD, the CEO and cofounder of Hemogenyx, said in a statement.
Let’s all invested hope some sort of pharma deal gets thrashed out via Prevail & Vlad
Around the Helix: Cell and Gene Therapy Company Updates – March 20, 2024
( Hemo on 2and page )
The cell and gene therapy sectors are growing exponentially, with new players emerging daily and much progress being made both in and out of the lab. CGTLive®'s Around the Helix is your chance to catch up with the latest news in cell and gene therapies, including partnerships, pipeline updates, and more.
Have a cell and gene therapy news update you'd like to share with our editorial team? Tag us on social and use #AroundTheHelix!
1. FDA Approves Liso-Cel (Breyanzi) as First CAR-T for CLL, SLL
The FDA has approved Bristol Myers Squibb's chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel; Breyanzi) for treating adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least 2 prior lines of therapy, including a Bruton tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor, under the accelerated approval pathway.
2. ODAC Meeting: Cilta-Cel Gets Unanimous Vote, Ide-Cel Wins Majority Vote for Benefit-Risk Profile
The FDA's Oncologic Drugs Advisory Committee (ODAC) Meeting has unanimously voted (11 yes, 0 no, 0 abstain) in favor of ciltacabtagene autoleucel's (cilta-cel; Janssen, Legend Biotech) benefit-risk profile for patients with relapsed and lenalidomide-refractory multiple myeloma (MM) after at least 1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent.
3. FDA Approves Orchard Therapeutics' Gene-Edited Cell Therapy Arsa-Cel for Metachromatic Leukodystrophy
The FDA has approved Orchard Therapeutics' gene-edited cell therapy atidarsagene autotemcel (arsa-cel, previously referred to as OTL-200 and now marketed in the US under the name Lenmeldy), for the treatment of children with presymptomatic late infantile, PS early juvenile, or early symptomatic early juvenile metachromatic leukodystrophy (MLD). Several days after the approval Orchard announced that the therapy will be priced at $4.25 million in the US.
4. Patients With Hemophilia Biding Their Time for Gene Therapy
Many patients with hemophilia A/B are content with their current treatment regimens and only a minority are currently eager to undergo gene therapy, presenting a challenge in attempting to establish best practices for informed consent with the treatment mode.
5. ImmPACT Bio Secures Grant to Bring CD19/CD20 Bispecific CAR-T to Lupus
ImmPACT Bio has received an $8 million grant from the California Institute for Regenerative Medicine that will help support clinical development of IMPT-514, an investigational CAR-T that is currently being evaluated in a phase 1b/2 clinical trial for the treatment of refractory lupus nephritis and systemic lupus erythematosus.
6. Cartherics to Try CAR-NK Cell Therapy Targeted at Tissue Factor Via Agreement With Ohio State University
Continues
MR I & all
Don’t give a monkeys if it’s a man , women or alien
It’s toxic & talks bo11ocks
I’ve posted every day for two weeks since having treatment & 8 of them were red , so factually he’s incorrect & irritating ,
He/she is a dipping trader who goads when the narrative doesn’t suit the trade , & the goading appears ,
‘ It springs up like a toxic blow up doll in the back of Del Boys van ‘
Pump & all
It’s relevant to anyone invested & just info .
Where as you & your pathetic comments backed up with silly emojis are completely irrelevant
You mentioned previously you have a partner , Jesus Christ I pity them listening to you on a daily basis , petty & toxic don’t cover it .